The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.

Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.

But the ESMO discussant recommends against widespread use in hormone-sensitive disease.

Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.

But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.

Artios, Synnovation and Novartis show mere glimmers of activity.